Cargando…

Restaging the Biochemical Recurrence of Prostate Cancer with [(68)Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management

SIMPLE SUMMARY: We aimed to evaluate the diagnostic performance, impact on patient disease management, and therapy efficacy prediction of [(68)Ga]Ga-PSMA-11 PET/CT on 294 patients with biochemical recurrence of prostate cancer. We established a composite standard of truth for the imaging based on al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fourquet, Aloÿse, Lahmi, Lucien, Rusu, Timofei, Belkacemi, Yazid, Créhange, Gilles, de la Taille, Alexandre, Fournier, Georges, Cussenot, Olivier, Gauthé, Mathieu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038030/ https://www.ncbi.nlm.nih.gov/pubmed/33808301 http://dx.doi.org/10.3390/cancers13071594

Ejemplares similares

(68)Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients’ disease management and adequacy of impact
por: Fourquet, Aloÿse, et al.
Publicado: (2020)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer
por: Barakat, Andrew, et al.
Publicado: (2020)

Dual-Time Point [(68)Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer
por: Hoffmann, Manuela A., et al.
Publicado: (2020)

Combined Intravenous Urogram and 68Ga-PSMA PET/ CT for Improved Staging and Restaging of Prostate Cancer
por: McBean, Rhiannon, et al.
Publicado: (2020)

Cyclotron-based production of (68)Ga, [(68)Ga]GaCl(3), and [(68)Ga]Ga-PSMA-11 from a liquid target
por: Rodnick, Melissa E., et al.
Publicado: (2020)

Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer
por: von Eyben, Rie, et al.
Publicado: (2023)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

In vitro and in vivo comparative study of a novel (68)Ga-labeled PSMA-targeted inhibitor and (68)Ga-PSMA-11
por: Chen, Huanyu, et al.
Publicado: (2021)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68)Ga‐PSMA‐11 PET Using Cyclotron‐Produced (68)Ga
por: Thompson, Scott M., et al.
Publicado: (2021)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

What to Trust, PSA or [(68)Ga]Ga-PSMA-11: Learn from Experience
por: Viglialoro, Rita, et al.
Publicado: (2021)

Comparison of Diagnostic Efficacy of [(68)Ga]Ga-FAPI-04 and [(18)F]FDG PET/CT for Staging and Restaging of Gastric Cancer
por: Zhang, Shumao, et al.
Publicado: (2022)

Differences in Distribution and Detection Rate of the [(68)Ga]Ga-PSMA Ligands PSMA-617, -I&T and -11—Inter-Individual Comparison in Patients with Biochemical Relapse of Prostate Cancer
por: Gühne, Falk, et al.
Publicado: (2021)

Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
por: Rosar, Florian, et al.
Publicado: (2023)

Prostate Cancer Biochemical Recurrence Resulted Negative on [(68)Ga]Ga-PSMA-11 but Positive on [(18)F]Fluoromethylcholine PET/CT
por: Laudicella, Riccardo, et al.
Publicado: (2022)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer
por: Wang, Guochang, et al.
Publicado: (2023)

[(68)Ga]Ga-PSMA and [(68)Ga]Ga-RM2 PET/MRI vs. Histopathological Images in Prostate Cancer: A New Workflow for Spatial Co-Registration
por: Ghezzo, Samuele, et al.
Publicado: (2023)

PSMA Expression in Multinodular Thyroid Neoplasm on Simultaneous Ga-68-PSMA PET/MRI
por: Jena, Amarnath, et al.
Publicado: (2017)

Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by (68)Ga-PSMA PET/CT
por: Christensen, Mads T., et al.
Publicado: (2022)

Automated synthesis and quality control of [(99m)Tc]Tc-PSMA for radioguided surgery (in a [(68)Ga]Ga-PSMA workflow)
por: Aalbersberg, Else A., et al.
Publicado: (2020)

[(68) Ga]Ga-PSMA-11 in diagnosis and follow-up after transarterial chemoembolization in hepatocellular carcinoma
por: Kunikowska, Jolanta, et al.
Publicado: (2023)

PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [(68)Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression
por: Rosar, Florian, et al.
Publicado: (2022)

[(68)Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [(177)Lu]Lu-PSMA therapy in relapsing high-grade glioma
por: Truckenmueller, Peter, et al.
Publicado: (2022)

Optimization of Automated Radiosynthesis of Gallium-68-Labeled PSMA11 with Two [(68)Ge]Ge/[(68)Ga]Ga Generators: Fractional Elution or Prepurification?
por: Durieux, Flore, et al.
Publicado: (2023)

Investigation of the halo-artifact in (68)Ga-PSMA-11-PET/MRI
por: Heußer, Thorsten, et al.
Publicado: (2017)

Mild (68)Ga PSMA-11 Uptake in Incidental Pituitary Adenoma
por: Beyhan, Ediz, et al.
Publicado: (2022)

Quantitative [(68)Ga]Ga-PSMA-11 PET biomarkers for the analysis of lesion-level progression in biochemically recurrent prostate cancer: a multicentre study
por: Kendrick, Jake, et al.
Publicado: (2023)

Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
por: Dietlein, Markus, et al.
Publicado: (2015)

The value of (68)Ga-PSMA enhanced PET-CT and MR-PET in patients with biochemical recurrent prostate cancer
por: Rummeny, E, et al.
Publicado: (2015)

(68)Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer
por: Iravani, Amir, et al.
Publicado: (2017)

One-year experience with (68)Ga-PSMA PET/CT: applications and results in biochemical recurrence of prostate cancer
por: Prado Júnior, Luciano Monteiro, et al.
Publicado: (2018)

Optimal MRI sequences for (68)Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer
por: Lake, Spencer T., et al.
Publicado: (2017)

Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative (68)Ga-PSMA-11 PET/CT
por: Qiu, Xuefeng, et al.
Publicado: (2021)

Hybrid imaging with [(68)Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer
por: Glemser, P. A., et al.
Publicado: (2022)

Cost-effectiveness of the implementation of [(68)Ga]Ga-PSMA-11 PET/CT at initial prostate cancer staging
por: van der Sar, Esmée C. A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bjodfmfphokb7h67eaoait6spi